Imperial College London


Faculty of MedicineDepartment of Infectious Disease

Clinical Immunologist







457Medical SchoolSt Mary's Campus





I have been the Operations manager for the Future Vaccine Manufacturing Hub (  in the lab of Robin Shattock since 2022. This strategic partnership of researchers, national centres and industry, aims to revolutionise vaccine manufacturing, with a particular focus on LMIC.I am also an Hon Associate Professor at UCL.

I completed a PhD in immunology and Genetics at Cambridge with Geoff Butcher in 1995 and an MSc in Epidemiology at Imperial College in 2007. I have diverse experience in the lab and field and a wide interest in public health. I have worked in vaccines since 2007 and remain primarily focussed on  the search and delivery of equitable public health interventions . My move from the lab into clinical immunology came after life changing experiences in South Africa and Namibia and an MSc in Modern Epidemiology in 2007. I then had the good fortune work with Sheena McCormack and have  >15 years experience working in clinical trials for infectious disease such as HIV, Covid-19 and Lassa fever. I have been able to remain involved in HIV prevention throughout; most recently through PrEPVacc ( - the first ever European funded Phase IIb vaccine trial. I am involved in the Imperial network for Vaccine research (

I am committed to improving vaccine literacy ( and supported Covid-19 outreach activities for the BSI in 2021

I have lived and worked in Namibia, South Africa, Uganda, Kenya, Mozambique and Tanzania and remain committed to and involved in supporting scientific research in those countries. I  have field experience in Schistosomiasis, Malaria, TB and HIV research in endemic countries.

I continue to learn from all my far flung collaborators and am very interested in all aspects of all cultures. I am a trustee of the Volunteer Centre Greenwich and  a very enthusiastic printmaker.



Kitonsa J, Kamacooko O, Ruzagira E, et al., 2023, A phase I COVID-19 vaccine trial among SARS-CoV-2 seronegative and seropositive individuals in Uganda utilizing a self-amplifying RNA vaccine platform: screening and enrollment experiences, Human Vaccines and Immunotherapeutics, Vol:19, ISSN:1554-8600, Pages:1-8

Horvath A, Rogers L, Pollakis G, et al., 2023, Systematic comparison of HIV-1 Envelope-specific IgG responses induced by different vaccination regimens: Can we steer IgG recognition towards regions of viral vulnerability?, Frontiers in Immunology, Vol:13, ISSN:1664-3224, Pages:1-16

Gombe B, Streatfield C, Leal L, et al., 2022, Optimization and validation of an ELISA assay for the determination of antibody responses to CN54gp140 and AIDSVAX BE for use in the Phase IIb PrEPVacc vaccine trial, Plos One, Vol:17, ISSN:1932-6203

Dalel J, Ung SK, Hayes P, et al., 2021, HIV-1 infection and the lack of viral control are associated with greater expression of interleukin-21 receptor on CD8(+) T cells, Aids, Vol:35, ISSN:0269-9370, Pages:1167-1177

Makinde J, Nduati EW, Freni-Sterrantino A, et al., 2021, A novel sample selection approach to aid the identification of factors that correlate wth the control of HIV-1 infection, Frontiers in Immunology, Vol:12, ISSN:1664-3224, Pages:1-12

More Publications